OPKO Health, Inc.

49 clinical trials · Sponsor

Record	Firm	Date
Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants (NCT07512427)	OPKO Health, Inc.	2026-07-24
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants (NCT07494045)	OPKO Health, Inc.	2026-06-01
Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism (NCT05543928)	OPKO Health, Inc.	2023-01-31
Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19 (NCT04551911)	OPKO Health, Inc.	2020-11-02
A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations (NCT03810664)	OPKO Health, Inc.	2019-01-18
Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects (NCT03660800)	OPKO Health, Inc.	2018-08-20
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI (NCT03602261)	OPKO Health, Inc.	2018-07-09
Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency (NCT03588884)	OPKO Health, Inc.	2018-06-08
Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects (NCT03406377)	OPKO Health, Inc.	2018-04-02
Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) (NCT03297398)	OPKO Health, Inc.	2018-02-21
Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency (NCT03874013)	OPKO Health, Inc.	2017-12-07
4Kscore Using Serum Stored Uncentrifuged (NCT04130776)	OPKO Health, Inc.	2017-10-04

Track OPKO Health, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.